Plasminogen activator inhibitor from human endothelial cells. Purification and partial characterization.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  European Journal of Biochemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 3496217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monoclonal Antibodies to Human 54,000 Molecular Weight Plasminogen Activator Inhibitor from Fibrosarcoma Cells - Inhibitor Neutralization and One-Step Affinity Purification

  1986cited by this paper
• Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family.

  1986cited by this paper
• Immunological Relationship Between the Fast-Acting Plasminogen Activator Inhibitors from Plasma, Blood Platelets and Endothelial Cells Demonstrated with a Monoclonal Antibody Against an Inhibitor from Placenta

  1986cited by this paper
• The use of human endothelial cells cultured in flat wells and on microcarrier beads to assess tissue plasminogen activator and factor VIII related antigen release.

  1986cited by this paper
• Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass

  1986cited by this paper
• Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells.

  1986cited by this paper
• Immunocytochemical staining of rat tissues with antibodies to denatured type I collagen: a technique for localizing areas of collagen degradation.

  1986cited by this paper
• Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor.

  1986cited by this paper
• Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line.

  1986cited by this paper
• The complete amino acid sequence of chicken skeletal-muscle enolase.

  1986cited by this paper
• The plasma inhibitors of plasminogen activator, studied by a zymographic technique.

  1985cited by this paper
• Platelet release protein which inhibits plasminogen activators.

  1985cited by this paper
• Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants.

  1985cited by this paper
• The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related.

  1985cited by this paper
• Evidence for the Occurrence of a Fast-Acting Inhibitor for Tissue-Type Plasminogen Activator in Human Plasma

  1984cited by this paper
• Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma.

  1984cited by this paper
• Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor.

  1984cited by this paper
• Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.

  1984cited by this paper
• Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.

  1984cited by this paper
• Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex.

  1984cited by this paper
• Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.

  1984cited by this paper
• Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium.

  1984cited by this paper
• Quantitation by Radioimmunoassay of Thrombospondin Synthesised and Secreted by Human Endothelial Cells

  1984cited by this paper
• Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.

  1983cited by this paper
• Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells.

  1983cited by this paper
• Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells.

  1983cited by this paper
• Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.

  1983cited by this paper
• A Simple, Sensitive Spectrophotometric Assay for Extrinsic (Tissue-Type) Plasminogen Activator Applicable to Measurements in Plasma

  1982cited by this paper
• "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.

  1981cited by this paper
• On the Regulation and Control of Fibrinolysis

  1980cited by this paper
• Purification and partial characterization of plasminogen activator from human uterine tissue.

  1979cited by this paper
• A high resolution PAS stain for polyacrylamide gel electrophoresis.

  1973cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow.

  2015cites this paper
• Characterisation, development and application of a clinical model of thrombosis and fibrinolysis

  2014cites this paper
• Effect of the small molecule plasminogen activator inhibitor‐1 (PAI‐1) inhibitor, PAI‐749, in clinical models of fibrinolysis

  2010cites this paper
• Myocardial Infarction Occurs with a Similar 24 h Pattern in the 4G/5G Versions of Plasminogen Activator Inhibitor-1

  2009cites this paper
• TAFIa, PAI‐1 and α2‐antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots

  2007cites this paper
• The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors

  2004cites this paper
• Plasminogen activator inhibitor-1.

  2004cites this paper
• Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies.

  2003cites this paper
• Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.

  2002cites this paper
• Regulation of plasminogen activation by TGF-β in cultured human retinal endothelial cells

  2000cites this paper
• Effective lysis of model thrombi by a t‐PA mutant (A473S) that is resistant to α2‐antiplasmin

  2000cites this paper
• Plasminogen activator inhibitor 2 and urokinase‐type plasminogen activator in plasma and leucocytes in patients with severe sepsis

  2000cites this paper
• Monocyte Plasminogen Activator Inhibitor 2 (PAI-2) Inhibits u-PA-mediated Fibrin Clot Lysis and Is Cross-linked to Fibrin

  1999cites this paper
• High‐level expression of active human plasminogen activator inhibitor type 1 (PAI‐1) in E. coli

  1996cites this paper
• Inhibitors of fibrinolysis are elevated in atherosclerotic plaque.

  1996cites this paper
• Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms.

  1995cites this paper
• Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli.

  1994cites this paper
• Plasminogen activator inhibitors (PAI‐1 and PAI‐2) in normal pregnancies, pre‐eclampsia and hydatidiform mole

  1994cites this paper
• Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.

  1994cites this paper
• Separation of active and inactive forms of recombinant human plasminogen activator inhibitor type 1 (PAI-1) expressed in Chinese hamster ovary cells: comparison with native human PAI-1.

  1994cites this paper
• Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.

  1994cites this paper
• The Roles of α2-Antiplasmin and Plasminogen Activator Inhibitor 1 (PAI-1) in the Inhibition of Clot Lysis

  1993cites this paper
• Multicenter Evaluation of Commercially Available Methods for the Immunological Determination of Plasminogen Activator Inhibitor-1 (PAI-1)

  1993cites this paper
• Constitutive biosynthesis of plasminogen activator inhibitor type‐1 (PAI‐1) by cultured human aortic endothelial cells independent of insulin

  1993cites this paper
• Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution.

  1992cites this paper
• Purification and characterization of active and latent forms of recombinant plasminogen activator inhibitor 1 produced in Escherichia coli.

  1992cites this paper
• Lysis of Platelet‐rich Thrombi: The Role of PAI–1 a

  1992cites this paper
• Tissue‐type plasminogen activator and its inhibitor in human glomerulonephritis

  1992cites this paper
• A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate.

  1992cites this paper
• Blood Coagulation and Fibrinolysis During Normal Pregnancy

  1991cites this paper
• Inhibition of a cell surface protease after cisplatin chemotherapy.

  1991cites this paper
• The receptor for tissue plasminogen activator (t‐PA) in complex with its inhibitor, PAI‐1, on human hepatocytes

  1991cites this paper
• The cloning and DNA sequence of the gene for the glutathione‐regulated potassium‐efflux system KefC of Escherichia coli

  1991cites this paper
• The inhibitor reacting with a tumour cell surface protease can be exchanged with plasminogen activator inhibitor (PAI-1).

  1991cites this paper
• Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system.

  1991cites this paper
• Evidence for the functional similarity between tumour cell surface guanidinobenzoatase and tissue type plasminogen activator.

  1991cites this paper
• The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit.

  1990cites this paper
• Purification and characterization of human plasminogen activator inhibitor type I expressed in Saccharomyces cerevisiae.

  1990cites this paper
• Purification and characterization of recombinant plasminogen activator inhibitor-1 from Escherichia coli.

  1990cites this paper
• High-level synthesis of biologically active human plasminogen activator inhibitor type 1 (PAI-1) in Escherichia coli.

  1990cites this paper
• Effects of recombinant plasminogen activator inhibitor type 1 on fibrinolysis in vitro and in vivo.

  1990cites this paper
• Plasminogen activator inhibitor-type I is a major biosynthetic product of retinal microvascular endothelial cells and pericytes in culture.

  1989cites this paper
• Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.

  1989cites this paper
• Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin.

  1989cites this paper
• An Enzyme-Linked Immunosorbent Assay (ELISA) Used to Study the Cellular Secretion of Endothelial Plasminogen Activator Inhibitor (PAI-1)

  1988cites this paper
• Bovine endothelial cell plasminogen activator inhibitor. Purification and heat activation.

  1988cites this paper
• Plasminogen activator inhibitor (PAI‐1) in plasma and platelets

  1988cites this paper
• A Plasminogen Activator Inhibitor (PAI-2) Circulates in Two Molecular Forms During Pregnancy

  1988cites this paper
• Fibrinolytic and Haemostatic Responses to Desamino-D-Arginine Vasopressin (DDAVP) Administered by Intravenous and Subcutaneous Routes in Healthy Subjects

  1988cites this paper